Please assess the completion status of the following clinical trial:

Trial Title: Treatment Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) in naïve Chronic Hepatitis B

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: OTHER
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Must have the ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures.~2. Adult male and non-pregnant, non-lactating female subjects, 19 years of age and older, based on the date of the screening visit. A negative serum pregnancy test at Screening is required for female subjects of childbearing potential (unless surgically sterile or greater than 2 years post-menopausal).~3. Documented evidence of chronic HBV infection (e.g. HBsAg positive for more than 6 months)~4. Chronic hepatitis B with the following:~   * HBeAg-positive and HBeAb negative at Screening~  * Screening HBV DNA ≥ 1x 105 copies/mL~  * Screening serum ALT level ≥ ×ULN(80 IU/L) and ≤ 10 ×ULN (by center laboratory range) OR~  * HBeAg-negative and HBeAb positive at Screening~  * Screening HBV DNA ≥ 1x 104 copies/mL~  * Screening serum ALT level ≥ ×ULN(80 IU/L) and ≤ 10 ×ULN (by center laboratory range) OR~  * Cirrhosis at Screening~  * Screening HBV DNA ≥ 1x 104 copies/mL in HBeAg negative or~  * Screening HBV DNA ≥ 1x 105 copies/mL in HBeAg positive~  * Screening serum ALT level ≥ ×ULN and ≤ 10 ×ULN (by center laboratory range)~5. A patient who treating with TDF as a treatment-naïve for Hepatitis B. Treatment naïve subjects defined as no history of antiviral therapy or \< 12 weeks of oral antiviral treatment with any nucleoside or nucleotide analogue, including lamivudine or adefovir, clevudine, telbivudine, entecavir~6. Decompensated liver cirrhosis defined based on a Child-Turcotte-Pugh (CTP) score ≥ 7 (Child B and C) or presence with at least one episode of ascites, jaundice, hepatic encephalopathy or variceal bleeding~7. Any previous treatment with interferon (pegylated or non-pegylated) must have ended at least 6 months prior to the baseline visit~8. Must be willing and able to comply with all study requirements.~Exclusion Criteria:~Subjects who meet any of the following exclusion criteria are not to be enrolled in the study.~1. Pregnant women, women who are breastfeeding or who believe they may wish to become pregnant during the course of the study.~2. Co-infection with HCV, HIV~3. Evidence of hepatocellular carcinoma (e.g. α-fetoprotein\> 50 ng/mL or as evidenced by recent ultrasound or other standard of care measure)~4. Malignancy within 5 years prior to screening, with the exception of specific cancers that are cured by surgical resection (basal cell skin cancer, etc). Subjects under evaluation for possible malignancy are not eligible~5. Current alcohol or substance abuse judged by the investigator to potentially interfere with subject compliance~6. Currently receiving therapy with cytotoxic agent, nephrotoxic agents, or agents capable of modifying renal excretion~7. Any other clinical condition or prior therapy that, in the opinion of the Investigator, would make the subject unsuitable for the study or unable to comply with dosing requirements.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- tenofovir disoproxil fumarate monotherapy (Type: None): a group which treated with tenofovir disoproxil fumarate

Based on this trial design, predict the completion outcome and termination type (if applicable).